Hypertension, CKD, and NSAIDs Case Discussion | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Case Discussion ](https://mdster.com/blog?category=case-discussion) 4. Hypertension, CKD, and NSAIDs: A Family Medicine Case Discussion [ Case Discussion ](https://mdster.com/blog?category=case-discussion) Hypertension, CKD, and NSAIDs: A Family Medicine Case Discussion ================================================================== Albuminuric CKD, ACE inhibitor safety, and the 'triple whammy' in primary care [ MDster Editorial Team ](https://mdster.com/about) · Jul 18, 2026 · 8 min read · 131 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Board Review ](https://mdster.com/blog?tag=board-review) [ Family Medicine ](https://mdster.com/blog?tag=family-medicine) [ Chronic Kidney Disease ](https://mdster.com/blog?tag=chronic-kidney-disease) [ Hypertension ](https://mdster.com/blog?tag=hypertension) [ NSAIDs ](https://mdster.com/blog?tag=nsaids) ![Hypertension, CKD, and NSAIDs: A Family Medicine Case Discussion](https://mdster.com/storage/blog/images/hypertension-ckd-and-nsaids-a-family-medicine-case-discussion.jpg) Share this article Share this post On this page 1. [ Reading the vignette like an examiner ](#reading-the-vignette-like-an-examiner) 2. [ What should be on your differential? ](#what-should-be-on-your-differential) 3. [ Classifying the kidney disease ](#classifying-the-kidney-disease) 4. [ Why albuminuria matters more than many trainees think ](#why-albuminuria-matters-more-than-many-trainees-think) 5. [ Investigation priorities in clinic ](#investigation-priorities-in-clinic) 6. [ Management that actually changes outcomes ](#management-that-actually-changes-outcomes) 7. [ Start renoprotection, but fix the context first ](#start-renoprotection-but-fix-the-context-first) 8. [ ACE inhibitor monitoring: know the thresholds ](#ace-inhibitor-monitoring-know-the-thresholds) 9. [ The 'triple whammy' is physiology, not folklore ](#the-triple-whammy-is-physiology-not-folklore) 10. [ Fix the knee pain plan and the lifestyle drivers ](#fix-the-knee-pain-plan-and-the-lifestyle-drivers) 11. [ Clinical Application ](#clinical-application) 12. [ Key Points for Board Exams ](#key-points-for-board-exams) 13. [ Conclusion ](#conclusion) 14. [ Frequently Asked Questions ](#blog-faqs) 15. [ References ](#references-heading) On this page 1. [ Reading the vignette like an examiner ](#reading-the-vignette-like-an-examiner) 2. [ What should be on your differential? ](#what-should-be-on-your-differential) 3. [ Classifying the kidney disease ](#classifying-the-kidney-disease) 4. [ Why albuminuria matters more than many trainees think ](#why-albuminuria-matters-more-than-many-trainees-think) 5. [ Investigation priorities in clinic ](#investigation-priorities-in-clinic) 6. [ Management that actually changes outcomes ](#management-that-actually-changes-outcomes) 7. [ Start renoprotection, but fix the context first ](#start-renoprotection-but-fix-the-context-first) 8. [ ACE inhibitor monitoring: know the thresholds ](#ace-inhibitor-monitoring-know-the-thresholds) 9. [ The 'triple whammy' is physiology, not folklore ](#the-triple-whammy-is-physiology-not-folklore) 10. [ Fix the knee pain plan and the lifestyle drivers ](#fix-the-knee-pain-plan-and-the-lifestyle-drivers) 11. [ Clinical Application ](#clinical-application) 12. [ Key Points for Board Exams ](#key-points-for-board-exams) 13. [ Conclusion ](#conclusion) 14. [ Frequently Asked Questions ](#blog-faqs) 15. [ References ](#references-heading) The dangerous part of this annual review is not the office BP alone. It is the cluster: confirmed hypertension on home readings, chronic ibuprofen exposure, reduced eGFR, A3 albuminuria, obesity, nightly alcohol, and symptoms suggesting obstructive sleep apnea (OSA). In family medicine, that combination means you are not just treating BP—you are interrupting CKD progression and preventing medication-related AKI. [\[1\]](#cite-1 "Reference [1]") Reading the vignette like an examiner ------------------------------------- ### What should be on your differential? This is most likely primary hypertension with multiple amplifiers, but calling it “essential hypertension” and stopping there would miss the teaching point. The reversible contributors are as important as the diagnosis itself. [\[2\]](#cite-2 "Reference [2]") - NSAID-associated worsening of BP control, edema, and kidney perfusion. - Albuminuric CKD, which is both a target-organ consequence and a driver of further hypertension. - OSA as a secondary contributor, given obesity, loud snoring, and daytime fatigue. - Alcohol excess, which worsens BP and overall cardiovascular risk. [\[2\]](#cite-2 "Reference [2]") ClueWhy it changes managementDaily ibuprofenAdds a reversible renal and hemodynamic insultACR 32 mg/mmolMakes this albuminuric CKD; RAAS blockade becomes centralSnoring plus fatigueJustifies formal OSA evaluation, not reassurance That table is the practical pivot: this is a multimorbidity visit, not a routine BP recheck. [\[3\]](#cite-3 "Reference [3]") Classifying the kidney disease ------------------------------ By KDIGO CGA nomenclature, an eGFR of 52 mL/min/1.73 m² is **G3a**, and an ACR of 32 mg/mmol is **A3** because A3 begins above 30 mg/mmol. On the KDIGO prognosis grid, G3aA3 sits in a **very high-risk** category. Strictly, CKD requires abnormality for at least 3 months, so repeat testing confirms chronicity if prior data are unavailable. [\[4\]](#cite-4 "Reference [4]") > **Clinical Pearl:** A small creatinine rise after starting an ACE inhibitor is often a hemodynamic effect, not treatment failure. The red flags are a creatinine rise of **30% or more**, an eGFR fall of **25% or more**, persistent NSAID exposure, volume depletion, or potassium reaching **6.0 mmol/L or higher**. [\[3\]](#cite-3 "Reference [3]") ### Why albuminuria matters more than many trainees think Albuminuria is not a minor lab abnormality. It identifies glomerular injury, predicts faster CKD progression, and increases cardiovascular risk, which is why albuminuric CKD changes first-line antihypertensive choice. [\[4\]](#cite-4 "Reference [4]") Investigation priorities in clinic ---------------------------------- The next steps are focused, not exotic. Confirm persistence, identify reversible insults, and look for a secondary contributor you can actually act on. [\[4\]](#cite-4 "Reference [4]") - Repeat creatinine/eGFR and ACR to document persistence. - Review all prescribed and OTC nephrotoxins, especially ibuprofen-containing products. - Check baseline potassium before RAAS blockade and after each dose change. - Arrange formal OSA assessment because his symptom pattern meets a high-suspicion profile. [\[3\]](#cite-3 "Reference [3]") Management that actually changes outcomes ----------------------------------------- ### Start renoprotection, but fix the context first For adults with CKD, hypertension, and ACR above 30 mg/mmol, NICE recommends an ACE inhibitor or ARB, titrated to the highest tolerated licensed dose. In parallel, chronic oral NSAID exposure should be actively unwound rather than ignored. [\[3\]](#cite-3 "Reference [3]") BP targets deserve nuance. NICE targets clinic BP below 140/90 mmHg and home BP below 135/85 mmHg for most adults under 80; for CKD with ACR under 70 mg/mmol, NICE also aims for clinic systolic BP below 140 mmHg. KDIGO 2021 suggests standardized office SBP below 120 mmHg when tolerated, but that recommendation depends on proper standardized measurement, so clinical judgment dictates how aggressively to operationalize it in routine primary care. [\[1\]](#cite-1 "Reference [1]") ### ACE inhibitor monitoring: know the thresholds Check creatinine/eGFR and potassium before starting therapy and again **1 to 2 weeks** after initiation or dose escalation. If creatinine rises by less than 30% and eGFR falls by less than 25%, current guidance supports continuing and rechecking. If the creatinine rise reaches 30% or the eGFR fall reaches 25%, first look for volume depletion or concurrent NSAID use; if no reversible cause is found, reduce or stop the RAAS blocker. Stop for potassium **6.0 mmol/L or higher** after addressing other contributors to hyperkalemia. [\[3\]](#cite-3 "Reference [3]") ### The 'triple whammy' is physiology, not folklore The mechanism is straightforward: NSAIDs impair prostaglandin-mediated afferent vasodilation, ACE inhibitors/ARBs dilate the efferent arteriole, and diuretics lower effective circulating volume. The combined effect is a fall in intraglomerular pressure and GFR, especially during dehydration or hypotension. [\[5\]](#cite-5 "Reference [5]") Consequently, sick-day advice must be explicit. During vomiting, diarrhea, high fever, or poor oral intake, he should temporarily hold the ACE inhibitor/ARB and avoid NSAIDs; if a diuretic is later added, that is usually held as well. Restart once he is eating and drinking normally and the illness has resolved; local protocols vary, with many using 24 to 48 hours of recovery and some AKI guidance advising 2 to 3 days after symptom resolution. [\[2\]](#cite-2 "Reference [2]") ### Fix the knee pain plan and the lifestyle drivers For knee osteoarthritis, NICE recommends topical NSAIDs first and advises that any oral NSAID use should be at the lowest effective dose for the shortest possible time, with explicit attention to renal, gastrointestinal, liver, and cardiovascular toxicity. In this patient, the oral ibuprofen strategy has already declared itself unsafe. [\[6\]](#cite-6 "Reference [6]") Board-style lifestyle counseling should be quantifiable: - Reduce alcohol to **no more than 2 drinks/day** for men, and less is reasonable. - Limit sodium to **under 2,300 mg/day**, ideally toward **1,500 mg/day** for most adults. - Prescribe **at least 150 minutes/week** of moderate activity plus resistance exercise on **2 or more days/week**. - Aim for **at least 5% weight loss** as an initial target. [\[7\]](#cite-7 "Reference [7]") His snoring, fatigue, obesity, and hypertension also justify formal sleep evaluation. Questionnaires may help triage, but diagnosis of adult OSA still requires objective testing such as polysomnography or home sleep apnea testing in the appropriate setting. [\[8\]](#cite-8 "Reference [8]") Clinical Application -------------------- In practice, I would stop the chronic oral NSAID strategy, start an ACE inhibitor unless a contraindication emerges, document clear sick-day rules, and recheck creatinine and potassium in 1 to 2 weeks. At the same visit, I would set a concrete alcohol, sodium, weight, and exercise plan and initiate OSA workup rather than deferring it to “later.” [\[3\]](#cite-3 "Reference [3]") Key Points for Board Exams -------------------------- - eGFR **52** plus ACR **32 mg/mmol** classifies as **CKD G3aA3**, which carries **very high risk** on the KDIGO grid. [\[4\]](#cite-4 "Reference [4]") - In CKD with hypertension and ACR **above 30 mg/mmol**, an **ACE inhibitor or ARB** is first-line renoprotective therapy. [\[3\]](#cite-3 "Reference [3]") - Recheck **creatinine/eGFR and potassium in 1 to 2 weeks** after starting or increasing ACEi/ARB therapy. [\[3\]](#cite-3 "Reference [3]") - Investigate or stop/reduce therapy if **creatinine rises 30% or more**, **eGFR falls 25% or more**, or **potassium reaches 6.0 mmol/L or higher**. [\[3\]](#cite-3 "Reference [3]") - The 'triple whammy' is **NSAID + ACEi/ARB + diuretic**, with AKI risk driven by afferent constriction, efferent dilation, and volume depletion. [\[5\]](#cite-5 "Reference [5]") Conclusion ---------- This case is classic board material because the numbers are only half the story. The real skill is recognizing albuminuric CKD early, choosing RAAS blockade safely, and removing the common primary-care hazards—NSAIDs, dehydration risk, alcohol excess, and unrecognized OSA—that turn stable CKD into preventable AKI. [\[3\]](#cite-3 "Reference [3]") Frequently Asked Questions ---------------------------- ### Is an ACR of 32 mg/mmol classified as A2 or A3? It is **A3** because KDIGO defines A3 albuminuria as **more than 30 mg/mmol**. [\[4\]](#cite-4 "Reference [4]") ### When should kidney function be rechecked after starting an ACE inhibitor in CKD? Check creatinine/eGFR and potassium **1 to 2 weeks** after starting the drug and again after each dose increase. [\[3\]](#cite-3 "Reference [3]") ### What rise in creatinine is acceptable after starting RAAS blockade? A modest hemodynamic rise can be acceptable, but a **30% or greater increase in creatinine** or **25% or greater fall in eGFR** should trigger evaluation for NSAIDs, volume depletion, or other causes and may require dose reduction or discontinuation. [\[3\]](#cite-3 "Reference [3]") ### Why is the NSAID-ACE inhibitor-diuretic combination so dangerous? Because it lowers glomerular filtration pressure from three directions at once: **afferent vasoconstriction** from NSAIDs, **efferent vasodilation** from ACEi/ARB therapy, and **volume depletion** from diuretics. [\[5\]](#cite-5 "Reference [5]") ### Should probable sleep apnea be addressed during a hypertension visit? Yes. Obesity, loud snoring, daytime sleepiness, and hypertension create a high-suspicion profile for OSA and justify objective sleep testing rather than watchful waiting alone. [\[8\]](#cite-8 "Reference [8]") References (15) ------------------- 1. 1. [ www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-managementpdf-66141722710213 ](https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-managementpdf-66141722710213) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ www.niddk.nih.gov/health-information/kidney-disease/keeping-kidneys-safe ](https://www.niddk.nih.gov/health-information/kidney-disease/keeping-kidneys-safe) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ www.nice.org.uk/guidance/ng203/chapter/Recommendations ](https://www.nice.org.uk/guidance/ng203/chapter/Recommendations) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf ](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ www.nhsbsa.nhs.uk/sites/default/files/2019-02/Medication%20Safety%20-%20Indicators%20Specification.pdf ](https://www.nhsbsa.nhs.uk/sites/default/files/2019-02/Medication%20Safety%20-%20Indicators%20Specification.pdf) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ www.nice.org.uk/guidance/ng226/chapter/Recommendations ](https://www.nice.org.uk/guidance/ng226/chapter/Recommendations) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ www.jacc.org/doi/10.1016/j.jacc.2025.05.007 ](https://www.jacc.org/doi/10.1016/j.jacc.2025.05.007) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ www.aasm.org/resources/clinicalguidelines/diagnostic-testing-osa.pdf ](https://www.aasm.org/resources/clinicalguidelines/diagnostic-testing-osa.pdf) [↩](#cite-ref-8-1 "Back to text") 9. 9. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024. 10. 10. NICE NG203: Chronic kidney disease: assessment and management. 11. 11. NICE NG136: Hypertension in adults: diagnosis and management. 12. 12. NICE NG226: Osteoarthritis in over 16s: diagnosis and management. 13. 13. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. 14. 14. Renal Association Clinical Practice Guideline: Acute Kidney Injury. 2019. 15. 15. American Academy of Sleep Medicine Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea. 2017. Study pathway Stay consistent in Family Medicine prep with a guided pathway --------------------------------------------------------------- - Broad coverage without the overwhelm - Short daily sessions that compound - See your progress and focus on weak areas Free 5-day trial No credit card required. [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Family Medicine ](https://mdster.com/speciality/family-medicine) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Board Review ](https://mdster.com/blog?tag=board-review) [ # Family Medicine ](https://mdster.com/blog?tag=family-medicine) [ # Chronic Kidney Disease ](https://mdster.com/blog?tag=chronic-kidney-disease) [ # Hypertension ](https://mdster.com/blog?tag=hypertension) [ # NSAIDs ](https://mdster.com/blog?tag=nsaids) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Case Discussion ----------------------- [ See all ](https://mdster.com/blog?category=case-discussion) [### Fire-Setting in Schizophrenia and Intellectual Disability 6 min read Aug 31, 2026 ](https://mdster.com/blog/fire-setting-in-schizophrenia-and-intellectual-disability) [### Intimate Partner Violence in Primary Care: A High-Risk Case 5 min read Aug 29, 2026 ](https://mdster.com/blog/intimate-partner-violence-in-primary-care-a-high-risk-case) [### Infantile Hypertrophic Pyloric Stenosis: A Board-Style Case 5 min read Aug 27, 2026 ](https://mdster.com/blog/infantile-hypertrophic-pyloric-stenosis-a-board-style-case) Related Posts ------------- [ ![Functional Restoration in Chronic Pain: A Behavioral Playbook](https://mdster.com/storage/blog/images/functional-restoration-in-chronic-pain-a-behavioral-playbook.jpg) Medical Education ### Functional Restoration in Chronic Pain: A Behavioral Playbook Learn how to shift chronic pain care from symptom chasing toward function using trauma-informed communication, CBT, pacing, graded activity, and CBT-I. 5 min read 0 comments ](https://mdster.com/blog/functional-restoration-in-chronic-pain-a-behavioral-playbook) [ ![Fire-Setting in Schizophrenia and Intellectual Disability](https://mdster.com/storage/blog/images/fire-setting-in-schizophrenia-and-intellectual-disability.jpg) Case Discussion ### Fire-Setting in Schizophrenia and Intellectual Disability A board-focused forensic case exploring intellectual disability, psychosis-driven fire-setting, pyromania, criminal justice vulnerability, and risk management. 6 min read 0 comments ](https://mdster.com/blog/fire-setting-in-schizophrenia-and-intellectual-disability) [ ![Pediatric Liver Synthetic Dysfunction: INR and Vitamin K Trial](https://mdster.com/storage/blog/images/pediatric-liver-synthetic-dysfunction-inr-and-vitamin-k-trial.jpg) Medical Education ### Pediatric Liver Synthetic Dysfunction: INR and Vitamin K Trial Learn how INR reveals pediatric liver synthetic failure, when coagulopathy signals an emergency, and how the vitamin K trial separates deficiency from hepatocyte failure. 6 min read 0 comments ](https://mdster.com/blog/pediatric-liver-synthetic-dysfunction-inr-and-vitamin-k-trial) [ ![Intimate Partner Violence in Primary Care: A High-Risk Case](https://mdster.com/storage/blog/images/intimate-partner-violence-in-primary-care-a-high-risk-case.jpg) Case Discussion ### Intimate Partner Violence in Primary Care: A High-Risk Case A case-based approach to IPV screening, lethality assessment, trauma-related chronic pain, documentation, safety planning, and confidentiality in primary care. 5 min read 0 comments ](https://mdster.com/blog/intimate-partner-violence-in-primary-care-a-high-risk-case) [ ![Mood, Affect, and Emotional Reactivity: A High-Yield MSE Guide](https://mdster.com/storage/blog/images/mood-affect-and-emotional-reactivity-a-high-yield-mse-guide.jpg) Medical Education ### Mood, Affect, and Emotional Reactivity: A High-Yield MSE Guide Learn to distinguish mood from affect and assess range, congruence, lability, anhedonia, alexithymia, and emotional reactivity during the psychiatric MSE. 5 min read 0 comments ](https://mdster.com/blog/mood-affect-and-emotional-reactivity-a-high-yield-mse-guide) [ ![Infantile Hypertrophic Pyloric Stenosis: A Board-Style Case](https://mdster.com/storage/blog/images/infantile-hypertrophic-pyloric-stenosis-a-board-style-case.jpg) Case Discussion ### Infantile Hypertrophic Pyloric Stenosis: A Board-Style Case A board-focused discussion of pyloric stenosis covering diagnostic reasoning, ultrasound criteria, metabolic alkalosis, resuscitation, anesthesia, and feeding. 5 min read 0 comments ](https://mdster.com/blog/infantile-hypertrophic-pyloric-stenosis-a-board-style-case) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ Download on the App Store ](https://apps.apple.com/app/id6759168258) [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Curriculum](https://mdster.com/curriculum) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://apps.apple.com/app/id6759168258) [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept